Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

Core Viewpoint - The company has received regulatory approval for the sale of Tadalafil tablets (20mg) in Ghana, marking a significant step in its international expansion efforts [2] Group 1: Regulatory Approval - The company announced that it has obtained a Drug Registration Certificate from the Food and Drug Authority of the Republic of Ghana for Tadalafil tablets (20mg) [2] - This approval allows the company to legally sell Tadalafil tablets in Ghana, which is a PDE5 inhibitor used for treating erectile dysfunction and benign prostatic hyperplasia symptoms [2] Group 2: Financial Impact - The projected sales revenue for Tadalafil tablets in the fiscal year 2024 is approximately 23.08 million RMB [2] - The company anticipates that the acquisition of the Drug Registration Certificate will not have a significant impact on its recent operating performance [2]

Core Viewpoint - The company has received approval from the Ghana Food and Drug Administration for the registration of Tadalafil tablets (20mg), allowing for legal sales in Ghana [1] Group 1: Product Approval - The approval signifies that Tadalafil tablets (20mg), a PDE5 inhibitor used for treating erectile dysfunction and benign prostatic hyperplasia symptoms, can now be marketed in Ghana [1] - The registration certificate is a crucial step for the company to expand its market presence in West Africa [1] Group 2: Financial Impact - The projected sales revenue for Tadalafil tablets in the fiscal year 2024 is estimated at 23.0793 million RMB [1] - The company anticipates that the approval will not have a significant impact on its recent operating performance [1]

Core Viewpoint - The company has received a drug registration certificate for Tadalafil Tablets (20mg) from the Food and Drugs Authority of Ghana, allowing for legal sales in the country, which supports the company's international market expansion efforts [1] Group 1: Product Approval - The drug Tadalafil (20mg) is classified as a PDE5 inhibitor, used for treating erectile dysfunction and symptoms of benign prostatic hyperplasia [1] - The approval marks a significant step for the company in establishing a presence in the Ghanaian market [1] Group 2: Market Impact - Currently, there is no established sales for Tadalafil in Ghana, and even with potential sales, the revenue contribution is expected to be low relative to the company's overall revenue [1] - The acquisition of the drug registration certificate is not anticipated to have a significant impact on the company's near-term operating performance [1]